Calcific Aortic Valve Disease: a Developmental Biology Perspective
Purpose of Review
This review aims to highlight the past and more current literature related to the multifaceted pathogenic programs that contribute to calcific aortic valve disease (CAVD) with a focus on the contribution of developmental programs.
Calcification of the aortic valve is an active process characterized by calcific nodule formation on the aortic surface leading to a less supple and more stiffened cusp, thereby limiting movement and causing clinical stenosis. The mechanisms underlying these pathogenic changes are largely unknown, but emerging studies have suggested that signaling pathways common to valvulogenesis and bone development play significant roles and include Transforming Growth Factor-β (TGF-β), bone morphogenetic protein (BMP), Wnt, Notch, and Sox9.
This comprehensive review of the literature highlights the complex nature of CAVD but concurrently identifies key regulators that can be targeted in the development of mechanistic-based therapies beyond surgical intervention to improve patient outcome.
KeywordsHeart valve Calcification Valvulogenesis Cell signaling Extracellular matrix
Calcific aortic valve disease (CAVD) is a public health problem affecting up to 13% of the population over the age of 65, and prevalence increases in the general population as the median age rises . Twenty five percent of people aged over 65 have a 50% increased risk of cardiovascular related events, and if untreated, there is an associated risk of 80% over 5 years of progression to heart failure or death . This common cardiovascular disorder is characterized by an abnormal accumulation of calcium-rich nodules on the aortic surface and/or within the annular region of the valve cusp, leading to thickening termed sclerosis, limited movement, and stenosis (left ventricular outflow obstruction) . At present, surgical valve replacement remains the standard treatment option which comes with insuperable complications, financial burdens, and no guarantee of long-term success. Furthermore, there are no approved pharmacological treatments available to stop the progression or treat (reverse) CAVD. Therefore, there is an increasing critical need to develop new medical therapies.
The underlying etiology of CAVD is poorly understood, but clinical risk factors have been identified; many of these are common to other cardiovascular disorders including atherosclerosis. Elevated total cholesterol, low-density lipoprotein (LDL) triglycerides, decreased high-density lipoproteins, male sex, tobacco use, hypertension, and diabetes mellitus have been reported to increase the incidence of aortic stenosis [4, 5]. It is not yet clear how these environmental risk factors promote CAVD onset, but in atherosclerosis, infiltration of inflammatory response cells and endothelial cell dysfunction (oxidative stress) are associated [6, 7•]. In addition to these factors, there are reports of a genetic component with mutations in Notch1 being identified . Two percent of the population is born with bicuspid aortic valve (BAV), and approximately 50% of these patients will develop CAVD at an earlier age than individuals with tricuspid aortic valves [9, 10]. This premature onset is thought to be attributed to changes in the biomechanical environment and the abnormal mechanical stress elicited by the morphological defect. While this has been the accepted dogma in the field, the cause of abnormal mechanical stress in affected patients is largely unknown, and the mechanosensory pathways that promote calcific changes in susceptible patients have not been identified. This review provides a concise overview of the current literature related to the importance of structure-function relationships in healthy valves and the key molecular players that contribute to their formation. In addition, we discuss the re-activation of valvulogenesis and bone development signaling pathways in the onset and progression of CAVD.
Structure-Function Relations of Healthy Aortic Heart Valves
Heart valves are dynamic structures opening and closing over 100,000 times a day to regulate unidirectional blood flow from the left ventricle to the rest of the body. There are two sets of cardiac valves: the atrioventricular (AV) valves, including the mitral and tricuspid that separate the atria from the ventricles, and the aortic and pulmonic semilunar valves that separate the ventricles from the great arteries. Although the functional demand of each valve set is similar, their anatomies are different. The AV valves are situated in the atrioventricular canal separating the atria from the ventricles. Structurally, these valves consist of two (mitral) or three (tricuspid) leaflets, with external supporting chordae tendineae that attach the leaflet to papillary muscles within the ventricles (reviewed in ). In contrast, the semilunar valves located at the base of the aorta and pulmonary trunk are comprised of three leaflets termed cusps and lack external chordae and papillary muscles, although a unique internal support structure has been described . It is the coordinated movement of these dynamic valvular structures that maintain unidirectional blood flow during the cardiac cycle. In diastole, the papillary muscles are relaxed and high pressure in the atrium causes opening of the mitral (left) and tricuspid (right) valve leaflets to promote blood flow into the respective ventricle. Once ventricular pressure increases during diastole, the chordae pull the atrioventricular valve leaflets closed and maintain coaptation to prevent eversion of the valve into the atria. As the ventricle contracts, blood exits through the now open semilunar valves and the ventricle relaxes to begin the cycle again. Therefore, throughout the cardiac cycle, the heart valve structures are exposed to constant changes in hemodynamic force as a result of pressure differences between systole to diastole. To withstand this complex mechanical environment, the valve leaflets/cusps develop and maintain an intricate and highly ordered connective tissue system .
Opening and closing of the valve leaflets or cusps is largely achieved by three organized layers of extracellular matrix (ECM) arranged according to blood flow direction, that each provide a unique biomechanical property to withstand the complex hemodynamics experienced with every cardiac cycle . The fibrosa layer is situated furthest away from blood flow and is largely composed of bundles of aligned fibrillar collagens that provide strength. Organized elastic fibers make up the ventricularis/atrialis (semilunar/atrioventricular) layer situated adjacent to blood flow. This matrix component allows for valve extension and recoil during each heartbeat . The proteoglycan-rich spongiosa layer is sandwiched between the fibrosa and ventricularis and provides compressibility in these load-bearing regions .
Homeostasis of the valve ECM is maintained by a heterogeneous population of valve interstitial cells (VICs) that, in healthy adults, are phenotypically similar to fibroblasts and express vimentin . The VICs largely serve to mediate physiological ECM remodeling within the leaflet/cusp in response to the normal wear and tear of aging. This is achieved through a balanced secretion of matrix degradation enzymes, including matrix metalloproteinases (MMPs) and their inhibitors (TIMPs), and deposition of structural matrix components within the three layers [19, 20]. Therefore, the VIC population plays a critical role in preserving the architecture of the valve for functional biomechanics. In addition to this cell population, the valve leaflet or cusp is encapsulated by a single cell layer of valve endothelial cells (VECs) that primarily functions as a barrier between the blood and the inner valve tissue, thereby protecting against the physical mechanical stress of the hemodynamic environment and preventing excess infiltration of circulating risk factors and inflammatory cells [21, 22]. In addition, VECs have been shown to molecularly communicate with underlying VICs to regulate their phenotype [23, 24]. VEC-specific disruption of essential signaling pathways in mice can alter VIC function and ECM organization leading to dysfunction [23, 25, 26, 27, 28]. Therefore, the integrity and function of the valve endothelium appears to be essential for maintaining structure-function relationships throughout life.
Aortic Valve Development
Formation of the highly ordered mature valve structure begins during embryonic (E) stages, around E9.5 in the mouse and E27 in humans. Prior to septation, the looped heart predominantly consists of cardiac myocytes and an overlying layer of endocardial cells that are separated by a hyaluronan-rich matrix, termed cardiac jelly. Specific to the atrioventricular canal and outflow tract regions, a subset of endocardial cells undergoes endocardial-to-mesenchymal transformation (EMT) and gives rise to swellings known as endocardial cushions, composed of mesenchymal cells embedded within a hyaluronan-rich ECM. Previous lineage tracing studies using endocardium-specific Cre mouse lines demonstrate that endothelially derived mesenchymal cells serve as precursors to the mature valve structures [29, 30]. The process of EMT is initiated in response to signals largely emanating from the adjacent myocardium and predominantly includes transforming growth factor-β (TGF-β) signaling. Studies in chick indicate important roles for the ligands TGF-β2 and TGF-β3 in early initiation steps [31, 32, 33], while in mice, endocardium-specific deletion of canonical Wnt signaling (β-catenin dependent) inhibits TGF-β-mediated induction of EMT, suggesting crosstalk between these signaling pathways . Bone morphogenetic protein (BMP) receptors and ligands are another major source of myocardially derived signals for EMT initiation [32, 35, 36, 37, 38, 39, 40, 41, 42]. Myocardium-specific knockdown of BMP2 severely disrupts VEC transformation, particularly in the atrioventricular canal, suggesting specificity to this valvular position . Furthermore, Notch signaling, predominantly in VECs, is a potent activator of EMT and roles for both receptors and ligands have been identified [27, 44, 45, 46, 47, 48, 49, 50, 51].
Following initiation of EMT, newly transformed mesenchymal cells then migrate and proliferate within expanded cardiac jelly and give rise to swellings known as endocardial cushions [33, 52]. In mice lacking TGF-β2, EMT is initiated; however, cushions are variably hypoplastic as a result of defects in migration and/or proliferation [53, 54], therefore suggesting differential roles for TGF-β signaling during cushion formation. Similar cushion defects are also observed in other mouse models with targeted downregulation of TGF-β signaling including endocardial deletion of TGF-βRI (Alk5)  and global deletion of the long form of latent TGF-β-binding protein 1, in which EMT initiation is impaired . In addition to TGF-β signaling, the transcription factor Sox9 has been shown to be a key player of proliferation of newly transformed mesenchymal cells. Targeted loss of Sox9 function using the endocardial Tie2cre line results in premature lethality around E11.5 due to a failure to expand the valve precursor cell pool within the endocardial cushions . The temporal window of EMT is somewhat diffuse, and while many positive regulators have been reported, few regulators to stop the process are known. Fate mapping using a valve endothelium-specific Cre mouse line shows that cells expressing a Nfatc1-enhancing region do not undergo EMT and remain in the endothelium . Therefore, EMT is a finely tuned process and studies in mice highlight the critical need to balance positive and negative regulators as genetically altered mice with severe cushion defects suffer premature lethality (reviewed in ).
The contribution of endocardially derived cells to the aortic valve precursor cell pool in the outflow tract and atrioventricular canal region was first demonstrated using the Tie2cre;Rosa26R reporter model, although it was noted that not all precursor cells recombine with the Tie2cre transgene [29, 30]. Following these studies, it was later shown that cells originating from the neural crest (Wnt1cre) and second heart field (Mef2ccre) also contribute to the semilunar valve precursor cell pool [59, 60, 61]. Interestingly, significantly less neural crest and secondary heart field-derived cells contribute to the mitral and tricuspid positions. However, these valves, unlike the semilunar valves, receive WT1-positive cells derived from the adjacent epicardium . While these developmental studies are informative, the field has yet to delineate the purpose or function of differential cell lineage contributions to the primitive atrioventricular and semilunar valve structures.
Once the valve precursor pool of mesenchymal cells has been established (around E14.5 in the mouse), the endocardial cushions undergo extensive remodeling as they elongate and thin into primordia. Cell proliferation is significantly reduced at this time, although proliferative cells remain enriched at the tip . Concurrently, precursor cells loose mesenchymal molecular markers including Twist1 but gain the activated myofibroblast marker, α-smooth muscle actin (α-SMA) . This phenotypic change is thought to reflect transition towards an activated valve interstitial cell (aVIC) that mediates physiological remodeling of the ECM during this stage of maturation. This includes breakdown of primitive cardiac jelly and synthesis of new ECM components that will later form the fibrosa, spongiosa, and ventricularis layers. However, direct evidence of embryonic aVIC function is lacking. The molecular regulators of mid-to-late valve development are largely unknown, but pathways important for EMT including TGF-β, BMP, Wnt, and Sox9 are also active during remodeling and have been shown to play differential roles at this stage (Gallina and Lincoln, unpublished) [57, 63, 64, 65]. More recently, additional regulators have been reported including hypoxia, cadherin-11 (cell adhesion), the chemokine receptor CXCR7, and the matrix remodeling enzyme ADAM17 [66, 67, 68, 69]. While mouse models with targeted genetic disruptions that result in valve remodeling defects are viable, it is considered that defects at this stage could underlie congenital valve malformations present at birth or potentially acquired disease manifested later in life.
The primitive valve continues to grow and mature after birth, and in the mouse, the three layers of predominant ECM components (collagen, proteoglycan, elastin) are apparent between postnatal days (PNDs) 7 and 10. At this time, cell proliferation is around 16.3% in VECs and ~ 15.2% in VICs (based on the 7-h pulse change of EdU) and cell division remains at this frequency until around PND 4 [12, 22] (Nordquist and Lincoln, unpublished). Concurrently, VICs lose α-SMA but maintain vimentin expression, suggesting transition towards a quiescent (or non-activated) fibroblast-like cell type . This quiescent phenotype is maintained throughout life in the absence of disease with cell proliferation estimated at a lower frequency of ~ 2.0% in VECs and ~ 1.1% in VICs (7-h pulse chase) . This level of normal adult cell turnover in the valve might be considered high compared to other cardiac cell types (< 1% in cardiac myocytes) ; however, the overall valve cell number does not appear to increase with aging (but matrix synthesis does) and, therefore, cell death likely occurs at a similar frequency; however, further studies are needed to determine this. The mechanism for maintaining adult valve cell population during the normal wear and tear of aging relies not only on resident cell proliferation but also on the contribution of extracardiac cells. Using mouse models to fate map CD45-positive cells, we and others have shown that under homeostatic conditions, ~ 2.3% of the valve cell population is derived from this lineage at postnatal stages and up to 10.3% at 6 weeks [71, 72, 73, 74]. It is speculated that loss or gain of VEC and VIC number might lead to perturbations in ECM homeostasis and subsequent biomechanical defects. In addition, the function of these cells is also important. In many cardiovascular disorders, endothelial cell dysfunction has been shown to play a major role. In the valves, we have shown that VECs have an overall decrease in nitric oxide availability, metabolism, membrane self-repair, and endothelial-to-mesenchymal transition potential with aging . Furthermore, studies have reported an age-associated loss in ECM organization and hemostatic protein regulation [75, 76], therefore suggesting that physiological regulators of valve homeostasis are sufficient to maintain structure-function relationships until the age of ~ 65 in otherwise healthy subjects or earlier in patients carrying known risk factors.
Calcific Aortic Valve Disease
CAVD is the most predominant form of valve pathology affecting more than 5.2 million people in the USA, particularly those over the age of 65 . In 2013, 50,222 deaths occurred due to valvular heart diseases in the USA, out of which 67.5% were due to aortic valve disorders . Traditionally, CAVD was seen as a degenerative process, as a result of aging of the aortic valve. However, several lines of evidence suggest that CAVD is an active disease with discernible initiating factors, including clinical and genetic predisposition, and dysregulation of molecular and cellular pathways that facilitate disease progression . Many of these factors are thought to be shared with atherosclerotic plaque formation and vascular calcification; however, parallels in pathogenic mechanisms remain elusive but warrant further investigation. At present, effective pharmacological treatments are lacking and interventional surgery or procedures to replace calcified or stenotic valves are the only effective option with no long-life guarantee . This clinical limitation has been largely attributed to our lack in understanding of CAVD pathogenesis. However, the field is growing and the mechanisms underlying disease onset and progression are emerging.
Published mouse models of calcific aortic valve disease
Associated human disease
Apoe−/− Apoe−/− on atherogenic diet
Thickened AoV, calcification, AS thickened AoV
Thickened AoV, calcification
Thickened AoV, calcification
Thickened AoV and PV
NOS3−/−;Notch1+/− fed Western diet
BAV, AoV calcification
AoV calcification, BAV
Notch1+/− on Western diet
BAV and AoV calcification
Thickened and calcified AoV
RBPJk1+/− fed HCVD diet
BAV, AoV calcification
Thickened AoV, calcification
C57BL/6J fed excess vitamin A diet
VDR−/− fed Western diet
LDLR−/− fed Western diet with low vitamin D
As discussed, the mechanisms that promote abnormal pro-osteogenic changes in valvular structures following exposure to risk factors or genetic predispositions are largely unknown. However, there are several reports that shed light on the biological processes that might be involved. One theory is that in response to pathological stimuli, resident VICs become activated as identified by positive α-SMA staining and transdifferentiate towards an osteoblast-like lineage. This is associated with abnormal activation of signaling pathways common to valve and bone development and expression of molecular markers observed in mineralized tissue, including Runx2, osteopontin, osteocalcin, bone sialoprotein, matrix Gla protein, and others [108, 109]. Although CAVD and bone mineralization share common mediators, they are quite different anatomically based on crystal size, mineral morphology, and elemental composition .
Several signaling pathways and transcription factors involved in endocardial cushion formation and bone development are reported to be dysregulated in CAVD. It remains unclear if abnormalities in these developmental regulators cause pro-osteogenic changes or are the effect of CAVD. Such pathways include TGF-β, implicated in the positive regulation of α-SMA during early VIC activation . However, it should be mentioned that the requirement of VIC activation for subsequent pro-osteogenic differentiation of VICs has not been directly tested. Explanted human aortic valves from CAVD patients with end-stage disease show increased expression of TGF-β1, and TGF-β1 treatment of ovine VICs is sufficient to promote calcification when cultured in osteogenic media, suggesting positive regulation [112, 113]. Similarly in developing bone, TGF-βs are pro-osteogenic, although it is the TGF-β2, but not TGF-β1 or TGF-β3, that is critical for inducing osteogenesis in mice [53, 114, 115, 116]. In contrast to this role, our group showed that TGF-β1 treatment of porcine VICs cultured on glass to promote pro-osteogenic changes prevented calcific nodule formation, and deletion of TGF-β1 in VECs causes CAVD in mice . These findings suggest that TGF-β plays pivotal roles in calcification which could be dependent on differential concentrations of endogenous or exogenous ligands, as previously described in osteoblast systems (reviewed in ).
The BMP family is named accordingly due to their requirement for bone formation. BMP2 is the major inducer of bone formation, but other ligands such as BMP7 may also mediate the osteogenic response through BMPR1A/ALK3, BMPR1B/ALK6, and AcvR1/ALK2 receptors [118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128]. Studies of calcified human valves show increased BMP2 and BMP4 expression and the expression of canonical BMP signaling mediator, pSmad1/5/8 [129, 130, 131]. The direct contribution of activated BMP signaling to CAVD pathogenesis has not been extensively examined. However, inhibition of BMP signaling by genetic inactivation of BMPR1A prevents CAVD in a susceptible mouse model (Klotho −/− ), and tissue-specific deletion of the Acvr1/ALK2 receptor leads to bicuspid aortic valve in mice and enhance pro-osteogenic changes during adulthood . Hence, BMPR1A is required for the valvular calcification while Acvr1 prevents BAV and subsequent nodule formation.
Canonical Wnt signaling (β-catenin dependent) is increased in calcified valves from human patients, mouse models, and cultured VICs [133, 134, 135, 136, 137, 138]. As with TGF-β signaling, it is not known if increased Wnt underlies the cause of CAVD or is a read-out of the end-stage process. Wnt activation promotes VIC activation  and, in other systems, promotes osteogenic differentiation of progenitor cells [139, 140] and induces calcification of vascular smooth muscle cells through β-catenin-mediated regulation of Runx2 . At present, the direct contribution of Wnt signaling to CAVD remains unclear, but these studies warrant further investigation.
As shown in Table 1, genetic alterations in Notch signaling family members promote CAVD in mice and human patients with Notch1 mutations correlate with aortic valve disease including calcification . Several groups have shed light on the mechanisms underlying the role of endothelially derived Notch1 receptor in calcification, and these include positive regulation of osteogenic inhibitors including matrix gla protein and Sox9 [95, 142]. At the level of the ligand, deletion of Jag1 in endothelially derived cells in mice leads to calcification associated with valve development defects . Notch activation favors BMP-induced osteoblast differentiation during skeletal development, and Notch inhibition represses BMP target genes [144, 145, 146]. Furthermore, BMP2 and TGF-β regulate expression of Notch pathway signaling proteins . Together, these findings highlight the crosstalk between Notch and osteogenic signaling pathways.
In addition to its role in valvulogenesis, Sox9 is an important mediator of CAVD. Initial studies of skeletal development identified Sox9 as a critical regulator of cartilage formation. In mouse chimeras, Sox9 −/− cells are excluded from all cartilage tissues and fail to express chondrocyte-specific markers . In addition, Sox9 haploinsufficiency leads to defective cartilage primordia and premature skeletal mineralization . The mechanisms of this inhibitory role for Sox9 in bone formation remain largely unknown, but Sox9 is known to inhibit Runx2 function at the protein level and directly represses its transactivation function on target genes [150, 151]. In the valves, we showed that reduced function of Sox9 during mid-stages of valvulogenesis is sufficient to promote early-onset CAVD in mice [57, 94], and this was mediated, in part, through de-repression of the osteogenic matrix protein Spp1 . The transcriptional activity of Sox9 on Runx2, Spp1, and potentially, other markers requires its nuclear localization. We have shown that reduced nuclear Sox9 precedes calcification of both mouse valves in vivo and pAVICS in vitro, and this is likely modulated through paracrine signals emanating from overlying VECs including TGF-β1, as well as regulation via nuclear export and import signals  (Dutta and Lincoln, unpublished).
Studies have shown that in parallel with pro-osteogenic fate changes in VICs during the development of CAVD, a significant contribution by extracellular vesicles (EVs) to the formation of calcific nodules is found and is localized at sites within the valve structure. EVs are membrane vesicles that are secreted from cells containing intracellular contents . They encompass a broad range of vesicles with varied features. Major types of EVs include microvesicles which are released from the budding of plasma membrane, and exosomes which originate from endosomes . The evidence of their presence has been validated via ultrastructural analysis and is found to be localized within medial arterial calcifications, atherosclerotic intimal plaques, and calcified human aortic valves . EVs serve as nucleating foci for calcific mineral crystallization via interacting with fibrillar collagen; however, the mechanism of this interaction and initiation of micro/macrocalcification remains unclear . Specific to aortic valve calcification and following endothelial cell dysfunction of diseased valves, EVs are thought to be derived from inflammatory cells including leukocytes, platelets, and endothelial cells themselves. These EVs promote VIC activation and subsequent fibrosis and mineralization . The molecular regulation of EVs in calcification is not well known, but recently, Aikawa’s group reported a novel role for the glycoprotein sortilin, which resides in calcifying vessels in human and mouse atheromata. Sortilin contributes to the formation of microcalcifications in smooth muscle cell culture through interaction with caveolin-1 and tissue non-specific alkaline phosphatase [154•]. While EVs have been observed in CAVD, the presence of vascular regulators remains unclear.
As discussed, there is a growing interest in discovering new molecular pathways in CAVD pathogenesis and the contribution of mechanical stress and flow to disease onset and progression continues to be an active area of investigation among biomedical engineering groups. The mechanical stimuli experienced by the aortic valve include shear stress strain, and pressure that alter strain/stress in the leaflet tissue . The aortic valve largely faces two kinds of stress: oscillatory flow or shear stress on the fibrosa side of the valve and laminar on the ventricularis side . The fibrosa layer of the valve predominantly experiences oscillatory shear, and this region is more prone to calcification than the ventricularis area that senses laminar shear. Simmons’ group has previously shown that endothelial cells on the fibrosa side express pro-osteogenic mediators while cells on the ventricularis surface express calcification inhibitors . However, it is not clear if the differential biomechanical environment, the diversity between VEC populations and location, and potentially, the development origin influence the profile of their mRNA expression. While the observation of oscillatory and laminar flow patterns has been known for many years, Dasi’s group more recently showed patient-specific differences in aorta anatomy that lead to differential flow patterns associated with calcific nodule formation at localized sites . These findings may help to explain the increased susceptibility in certain individuals including those with BAV that experience a drastic change in flow momentum caused by the eccentricity of the orifice jet as a result of two leaflets instead of three. More specific to strain, Merryman’s group has shown that subjecting VICs to strain using the Flexcell tension system following TGF-β1 treatment augments calcific nodule formed compared to no strain (with TGF-β1 treatment) . In addition, the positive contribution of mechanical strain to calcification has more recently been shown using the finite element method .
In conclusion, it remains unclear whether mechanical stress initiates pro-osteogenic changes or subtle changes in valve morphology and stiffness that lead to changes in flow pattern. Several decades ago, the fields of valve biology and valve bioengineering were distinct entities. Today, however, these two fields have been highly integrated in recent years in order to fully understand the multifaceted process of CAVD. While this is advantageous to those elucidating pathogenesis, the complexity of the biology makes the development of an alternative therapy challenging.
The management of CAVD has received increased attention over the last decade due to an increase in disease prevalence as the global population lives longer [160, 161]. In addition, there is a significant cohort of patients with severe symptomatic aortic stenosis that are left untreated, and others that develop left ventricular dysfunction before the onset of detectable aortic valve regurgitation [5, 80, 162, 163]. While the field works towards identifying biomarkers of CAVD and discovering new pharmacological-based treatment strategies, conventional surgery to replace the calcified and dysfunctional aortic valves remains the gold standard intervention for patients. However, data from large registries still show a mortality rate of 2–3% and this risk is increased in patients with comorbidities [164, 165, 166]. Mechanical and bioprosthetic valves are generally available for valve replacement surgeries. Mechanical valves are rigid and largely free from structural failure and therefore common in younger (aged under 50) CAVD patients with normal hemodynamics. However, due to the material composite, mechanical valves fail to remodel in the patient and are thrombogenic, requiring life-long anticoagulation therapy . The use of biological replacement valves has increased from 43.6% in 1997 to 78.4% in 2006 . These are the most commonly implanted xenograft material made from a native porcine valve or root or from bovine pericardium. Long-term anticoagulation is not required, and the hemodynamics is superior. However, unlike the mechanical valve, biological valves are prone to degenerative wear and tear like the native valve. In summary, the implantation of prosthetic aortic valves is not a perfect solution to CAVD and the field is in critical need of more effective alternatives.
Pharmacological initiatives in the treatment of CAVD have focused on targeting risk factors of CAVD in affected individuals, particularly elevated lipoprotein levels. The outcomes of administering oral statin therapy to lower LDL levels have been mixed. Despite some studies initially reporting benefits [168, 169, 170, 171, 172, 173], others have shown conflicting results, with some stating no beneficial effects on valve structure and function despite a significant drop in LDL cholesterol levels [174, 175, 176, 177, 178, 179, 180, 181]. Therefore, statin therapy for CAVD remains underprescribed and the field continues to explore better alternatives. Unfortunately, none to date has been found to work better than prosthetic valve replacement, which is likely due to the complex, multifactorial nature of this disease and the difficulty in targeting multiple contributing signaling pathways discussed in this review.
The pathogenesis of CAVD is complex, and its manifestations appear later in life likely resulting from long-term exposure to known risk factors, leading to altered biomechanics and re-activation of signaling pathways important in developing valves and bone. In addition to acquired diseases, it is also important to consider that CAVD in the elderly may have origins during valvulogenesis that increase susceptibility to changes after birth. The clinical management of CAVD patients is ever changing with advancements in imaging capabilities to improve diagnosis; however, treatment options remain a challenge and non-invasive approaches are limited. By gaining a more complete understanding of the molecular and cellular processes that prevent calcification in healthy valves and promote osteogenic-like changes in at-risk valves, we can move forward in developing alternative, mechanistic-based therapies to improve patient long-term outcome.
Compliance with Ethical Standards
Conflict of Interest
Punashi Dutta and Joy Lincoln have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 7.• Gimbrone MA Jr, Garcia-Cardena G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118(4):620–36. This paper provides an important and concise review of how dysfunction of the endothelial lining increases the susceptibility for atherosclerotic cardiovascular disease.PubMedPubMedCentralCrossRefGoogle Scholar
- 25.Huk DJ, Austin BF, Horne TE, Hinton RB, Ray WC, Heistad DD, et al. Valve endothelial cell-derived Tgfbeta1 signaling promotes nuclear localization of Sox9 in interstitial cells associated with attenuated calcification. Arterioscler Thromb Vasc Biol 2015.Google Scholar
- 54.Bartram U, Molin DG, Wisse LJ, Mohamad A, Sanford LP, Doetschman T, et al. Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-beta(2)-knockout mice. Circulation. 2001;103(22):2745–52.PubMedCrossRefGoogle Scholar
- 66.Amofa D, Hulin A, Nakada Y, Sadek HA, Yutzey KE. Hypoxia promotes primitive glycosaminoglycan-rich extracellular matrix composition in developing heart valves. Am J Physiol Heart Circ Physiol. (2017):ajpheart 00209 2017.Google Scholar
- 99.Barrick CJ, Roberts RB, Rojas M, Rajamannan NM, Suitt CB, O’Brien KD, et al. Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice. Am J Physiol Heart Circ Physiol. 2009;297(1):H65–75.PubMedPubMedCentralCrossRefGoogle Scholar
- 108.Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease-2011 update. Circulation. 2011;124(16):1783–91.PubMedPubMedCentralCrossRefGoogle Scholar
- 123.van Dinther M, Visser N, de Gorter DJ, Doorn J, Goumans MJ, de Boer J, et al. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J Bone Miner Res. 2010;25(6):1208–15.PubMedGoogle Scholar
- 133.Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol. 2006;47(8):1707–12.PubMedPubMedCentralCrossRefGoogle Scholar
- 154.• Goettsch C, Hutcheson JD, Aikawa M, Iwata H, Pham T, Nykjaer A, et al. Sortilin mediates vascular calcification via its recruitment into extracellular vesicles. J Clin Investig. 2016;126(4):1323–36. This study provides the first mechanistic insight into the contribution of extracellular vesicles to the formation of microcalcific lesions in the onset of cardiovascular calcification.PubMedPubMedCentralCrossRefGoogle Scholar
- 167.Brown JM, O’Brien SM, Wu C, Sikora JA, Griffith BP, Gammie JS. Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database. J Thorac Cardiovasc Surg. 2009;137(1):82–90.PubMedCrossRefGoogle Scholar
- 175.Chan KL, Teo K, Dumesnil JG, Ni A, Tam J, ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121(2):306–14.PubMedCrossRefGoogle Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.